FIG 2.

Genetic analysis of fluconazole-induced MTL-homozygous strains. Shown are the genetically engineered strains that are heterozygous for mutated TAC1* (SCTAC1R32A and -B), ERG11* (SCERG11R32A and -B), MRR1* (SCMRR1R32A), and UPC2* (SCUPC2R12A and -B) alleles and derivatives that became homozygous for MTLa or MTLα after growth in the presence of fluconazole. The parental wild-type reference strain SC5314 is included for comparison. A schematic showing the restriction site polymorphisms used to distinguish wild-type and mutated ERG11, MRR1, TAC1, and UPC2 alleles, the polymorphic wild-type GLN3 and CAP1 alleles, and the MTLa and MTLα loci, as well as the expected fragment sizes after hybridization with specific probes is presented in Fig. S2 in the supplemental material. Some blots are from independent genomic DNA preparations of the same strains, and differences in signal intensities are caused by unequal loading. The MIC (μg/ml) of fluconazole for each strain is given below the corresponding lane.